Drug ID: 1d00000006
Drug Name: Abciximab
Generic Names: Reopro |
Category: Anticoagulants / Antithrombotics
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category C:
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: IV - The recommended dose is 0.25mg/kg administered 10-60 minutes before procedure, which is followed by a continuous intravenous infusion of 0.125 µg/kg/min (to a maximum of 10 µg/min) for 12 hours.
Recommended In: This medication is an antithrombolytic agent (blood thinner) which is used to prevent blood clots during certain procedures used to open up the blood vessels in the heart (e.g., balloon angioplasty, coronary stent placement, percutaneous coronary intervention-PCI).
Directions For Use: It comes as a solution for injection to be administered by a healthcare provider into the vein.
Storage: Store at 2 to 8.8°C. Do not freeze. Do not shake. Do not use beyond the expiration date. Discard any unused portion left in the vial.
Dosage Forms: Intravenous Injection | Intravenous infusion
Side Effects: Heart - Low blood pressure, slow/fast heart rate, palpitations, fistula, abnormal heart rhythm, blood clot in lungs and inflammation of blood vessels.
Gastrointestinal - Nausea, vomiting, abdominal pain, indigestion, diarrhea, bloody/black/tarry stools, intestinal blockage and reflux.
Blood - Anemia, decrease in blood platelets, increased risk of bleeding (the most common type of bleeding is gastrointestinal hemorrhage)
Central Nervous System - Dizziness, anxiety, abnormal thinking, slurred speech, agitation, confusion, muscle contractions, coma, and increased muscle tone and double vision.
Respiratory - Pneumonia, lung inflammation, asthma, coughing up blood and blood clots in lung.
Musculoskeletal - Muscle pain.
Genitourinary - Urinary retention, painful urination, abnormal kidney function, frequent urination and urinary incontinence.
Miscellaneous - Back pain, chest pain, headache, injection site pain, swelling in the extremities,increased sweating, weakness, itching, pale/gray/bluish skin, abnormal vision, wound, pus, dry mouth, vomit that looks like coffee grounds, diabetes and abdominal bloating.
In Case of Overdose: There has been no experience of overdosage in human clinical trials.
Avoid If: Caution should be exercised in patients with history of clotting or blood disorders, internal bleeding (within 6 weeks) gastrointestinal or genitourinary bleeding, trauma in the head or spine (within 2 years), any allergy, during pregnancy and breastfeeding.
It may cause dizziness, do not drive a car or operate machinery while taking this medication.
It may reduce platelet counts; avoid injury or bruising.
Caution should be taken if the patient is currently on or will be receiving dextran by injection and is receiving or have received an anticoagulant (eg, warfarin) within the last 7 days.
Drug Interaction: Formal drug interaction studies with Abciximab have not been conducted. Abciximab has been administered to patients with ischemic heart disease treated concomitantly with a broad range of medications used in the treatment of angina, myocardial infarction and hypertension. These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin. Heparin, other anticoagulants, thrombolytics, and antiplatelet agents are associated with an increase in bleeding. Patients with HACA titers may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.